Filtered By:
Education: Study
Management: Food and Drug Administration (FDA)

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 209 results found since Jan 2013.

Biological Properties and Clinical Significance of Lipoprotein-Associated Phospholipase A < sub > 2 < /sub > in Ischemic Stroke
Cardiovasc Ther. 2022 Oct 14;2022:3328574. doi: 10.1155/2022/3328574. eCollection 2022.ABSTRACTIschemic stroke, which occurs following blockage of the blood supply to the brain, is a leading cause of death worldwide. Its main cause is atherosclerosis, a disease of the arteries characterized by the deposition of plaques of fatty material on the inner artery walls. Multiple proteins involved in the inflammation response have been identified as diagnosing biomarkers of ischemic stroke. One of these is lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme that can hydrolyze circulating oxidized phospholipids, generating...
Source: Atherosclerosis - October 31, 2022 Category: Cardiology Authors: Shuang Zhang Shuchun Huang Dingju Hu Fenglong Jiang Yanli Lv Guoqi Liu Source Type: research

Evolution of Stroke Prevention in Nonvalvular Atrial Fibrillation Patients ∗
The PREVAIL (Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) trial is the latest in the series of studies evaluating left atrial appendage (LAA) occlusion with the Watchman device (Boston Scientific, Natick, Massachusetts) as an alternative to warfarin therapy for the prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF). The PREVAIL trial was initially designed as a follow-up study to PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in Patients With Atrial Fibrillation), which demonstrated noninferiority to warfa...
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - July 3, 2014 Category: Radiology Source Type: research

FDA expands use window for stroke treatment device
The U.S. Food and Drug Administration (FDA) has expanded the treatment window...Read more on AuntMinnie.comRelated Reading: FDA clears Viz.AI's stroke detection software Study finds gadolinium leaks into eyes of stroke patients Perfusion imaging expands window for stroke treatment FDA clears 2 clot retrieval devices for stroke Interventionalists: Proceed with caution for mechanical blood clot removal
Source: AuntMinnie.com Headlines - February 15, 2018 Category: Radiology Source Type: news

Study of brain cooling and clot-busting drug therapy for stroke receives FDA OK to expand
This study, which includes the use of intravenous tissue plasminogen activator, the only FDA-approved treatment for acute stroke, is the latest in a series of clinical trials on brain cooling -- controlled hypothermia -- to reduce neurological damage after stroke.
Source: EurekAlert! - Medicine and Health - February 5, 2013 Category: Global & Universal Source Type: news

Watching, but not waiting: vascular neurology perspective on the disparate regulatory pathways for stroke
Vascular neurologists have keenly watched the Watchman device (Atritech, Plymouth, Minnesota, USA) regulatory approval process. We are, as always, searching for additional options in the prevention and treatment of stroke to better care for our patients, and new approaches to the management of atrial fibrillation play a large part in this effort. Recently, a Food and Drug Administration (FDA) panel voted 13:1 in favor of the Watchman device for the prevention of ischemic stroke in non-valvular atrial fibrillation.1 The panelists came to this decision after reviewing data from large randomized trials that compared anticoagu...
Source: Journal of NeuroInterventional Surgery - May 14, 2015 Category: Neurosurgery Authors: Sheth, S. A., Nogueira, R. G., Noorian, A. R., Liebeskind, D. S. Tags: Editorials Source Type: research

Hope for reversing stroke-induced long-term disability
Permanent brain damage from a stroke may be reversible thanks to a developing therapeutic technique, a study has found. The novel approach combines transplanted human stem cells with a special protein that the US Food and Drug Administration already approved for clinical studies in new stroke patients. The researchers say they are the first to use 3K3A-APC to produce neurons from human stem cells grafted into the stroke-damaged mouse brain.
Source: ScienceDaily Headlines - August 22, 2016 Category: Science Source Type: news

Prescription Doses of Fish Oil May Lower Heart Attack and Stroke Risk
Omega-3 fatty acids, abundant in fish oil, are known to be good for the heart. Studies have shown that people who eat more fish rich in these fats have lower rates of heart problems and less risk of dying from heart disease compared to those who eat less. Those data have fueled a booming business in over-the-counter fish oil supplements. In a new study published in the New England Journal of Medicine, and presented at the American Heart Association annual meeting, researchers report that a highly purified version of omega-3 fats, called icosapent ethyl, can lower the risk of a number of heart-related events, including hear...
Source: TIME: Health - November 10, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthytime Heart Disease omega-3 Source Type: news

Stroke After Transcatheter Aortic Valve Replacement
This study reported about a 7% risk of stroke, which was not surprising given the patient population and the likelihood of particulate embolization when expanding a new valve within the annulus of the stenosed and calcified native valve. Nevertheless, even with this stroke risk, there was a clear mortality benefit and quality of life was improved as well. After the PARTNER 1A high-risk cohort demonstrated similar or improved outcomes relative to open surgical aortic valve replacement (SAVR) in patients at high (but not inoperable) surgical risk, the US Food and Drug Administration (FDA) approved TAVR in 2011 and the proced...
Source: JAMA - June 18, 2019 Category: General Medicine Source Type: research

Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up?
Alteplase is the only Food and Drug Administration-approved intravenous (IV) thrombolytic medication for acute ischemic stroke. However, multiple recent studies comparing tenecteplase and alteplase suggest that tenecteplase is at least as efficacious as alteplase with regards to neurologic improvement. When given at 0.25 milligrams per kilogram (mg/kg), tenecteplase may have less bleeding complications than alteplase as well. This narrative review evaluates the literature and addresses the practical issues with regards to the use of tenecteplase versus alteplase for acute ischemic stroke, and it recommends that physicians ...
Source: Western Journal of Emergency Medicine - February 24, 2020 Category: Emergency Medicine Source Type: research

Tenecteplase for Acute Ischemic Stroke Treatment
Semin Neurol DOI: 10.1055/s-0040-1722722The introduction of thrombolytic therapy in the 1990s has transformed acute ischemic stroke treatment. Thus far, intravenous recombinant tissue plasminogen activator (rt-PA) also known as alteplase is the only thrombolytic proven to be efficacious and approved by the United States Food and Drug Administration. But the thrombolytic agent tenecteplase (TNK) is emerging as a potential replacement for rt-PA. TNK has greater fibrin specificity, slower clearance, and higher resistance to plasminogen activator inhibitor-1 than rt-PA. Hence, TNK has the potential to provide superior lysis wi...
Source: Seminars in Neurology - January 20, 2021 Category: Neurology Authors: Baird, Alison E. Jackson, Richard Jin, Weijun Tags: Review Article Source Type: research

Stem cell therapy promotes recovery from stroke and dementia in mice
A one-time injection of an experimental stem cell therapy can repair brain damage and improve memory function in mice with conditions that replicate human strokes and dementia,a new UCLA study finds.Dementia can arise from multiple conditions, and it is characterized by an array of symptoms including problems with memory, attention, communication and physical coordination. The two most common causes of dementia are Alzheimer ’s disease and white matter strokes — small strokes that accumulate in the connecting areas of the brain.“It’s a vicious cycle: The two leading causes of dementia are almost always seen togeth...
Source: UCLA Newsroom: Health Sciences - April 22, 2021 Category: Universities & Medical Training Source Type: news

The emerging role of FTY720 as a sphingosine 1 ‐phosphate analog for the treatment of ischemic stroke: The cellular and molecular mechanisms
Three important mechanisms for neuroprotective effects of FTY720 have been described. Functional antagonistic, functional agonistic and receptor-independent mechanisms. Here, we review these mechanisms in more details and describe animal model and in clinical trial studies AbstractFinding novel and effective drugs for the treatment of ischemic stroke is warranted because there is not a definitive treatment for this prevalent disease. Due to the relevance between the sphingosine 1-phosphate (S1P) receptor and several neurological diseases including ischemic stroke, it seems that fingolimod (FTY720), as an agonist of S1P rec...
Source: Brain and Behavior - May 10, 2021 Category: Neurology Authors: Maryam Naseh, Jafar Vatanparast, Ali Rafati, Mahnaz Bayat, Masoud Haghani Tags: REVIEW Source Type: research

tPA and warfarin: Time to move forward
The appropriate use of IV tissue plasminogen activator (tPA) for patients with acute ischemic stroke remains an area of active discussion among health care professionals. Since its approval in the United States by the Food and Drug Administration in 1996, the medical community has continued to review and discuss the risks vs benefits of this important therapy. Two recent publications1,2 and accompanying editorials have refocused attention on the vexing issue of using IV tPA in patients taking warfarin. The Xian et al.1 study found a 1.1% absolute increase in the risk of intracranial hemorrhage (ICH) with warfarin use (5.7%...
Source: Neurology - February 4, 2013 Category: Neurology Authors: Alberts, M. J., Naidech, A. M. Tags: All Cerebrovascular disease/Stroke EDITORIALS Source Type: research

PFO Closure for Cryptogenic Stroke: A Review and Clinical Treatment Algorithm
We describe the historical context of PFO closure and review the observational and randomized control trial evidence in this field, culminating in the recent Food and Drug Administration approval of the first dedicated closure device for PFO. Guidelines and consensus statements are discussed, and a novel treatment algorithm is proposed. Future directions in PFO closure will include new devices, further data from completed and upcoming clinical trials, and potential expansion into other disease states associated with PFO.
Source: Cardiology in Review - June 6, 2017 Category: Cardiology Tags: Review Articles Source Type: research